4//SEC Filing
Kelsey Stephen Michael 4
Accession 0001610717-25-000339
CIK 0001628171other
Filed
Sep 14, 8:00 PM ET
Accepted
Sep 15, 8:51 PM ET
Size
18.2 KB
Accession
0001610717-25-000339
Insider Transaction Report
Form 4
Kelsey Stephen Michael
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2025-09-11$4.73/sh+100,000$473,000→ 389,414 total - Sale
Common Stock
2025-09-15$45.92/sh−23,682$1,087,418→ 290,732 total - Sale
Common Stock
2025-09-15$46.93/sh−1,318$61,854→ 289,414 total - Exercise/Conversion
Common Stock
2025-09-15$4.73/sh+25,000$118,250→ 314,414 total - Sale
Common Stock
2025-09-11$43.58/sh−44,059$1,919,963→ 345,355 total - Sale
Common Stock
2025-09-11$44.48/sh−55,941$2,488,519→ 289,414 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-11−100,000→ 55,055 totalExercise: $4.73From: 2023-08-09Exp: 2029-08-08→ Common Stock (100,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-15−25,000→ 30,055 totalExercise: $4.73From: 2023-08-09Exp: 2029-08-08→ Common Stock (25,000 underlying)
Footnotes (6)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025.
- [F2]Includes 94,426 restricted stock units.
- [F3]The transaction was executed in multiple trades in prices ranging from $43.12 to $44.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]The transaction was executed in multiple trades in prices ranging from $44.12 to $44.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F5]The transaction was executed in multiple trades in prices ranging from $45.4650 to $46.46, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F6]The transaction was executed in multiple trades in prices ranging from $46.5450 to $47.21, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Documents
Issuer
Revolution Medicines, Inc.
CIK 0001628171
Entity typeother
Related Parties
1- filerCIK 0001462808
Filing Metadata
- Form type
- 4
- Filed
- Sep 14, 8:00 PM ET
- Accepted
- Sep 15, 8:51 PM ET
- Size
- 18.2 KB